Bioton SA

Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on diabetes management, offering products such as recombinant human and conventional insulin, alongside oral anti-diabetic medications. The company's portfolio extends to include dietary supplements, blood glucose monitoring strips, and over-the-counter solutions for diabetics. Key insulin products include Gensulin N, Gensulin R, and Gensulin M30, available in vials and cartridges. Complementing these are advanced delivery and monitoring systems like the GensuPen 2 automatic injection device and the GensuCare glucometer for diabetes monitoring, alongside essential needles. Bioton S.A. distributes its offerings across numerous international markets, including Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. Beyond its core product activities, the company also undertakes advertising, advisory services, and general corporate management. Founded in 1989, its headquarters are situated in Ozarów Mazowiecki, Poland.